iTeos Therapeutics, Inc. ITOS
Set alert
At close · Aug 29
52-week range unavailable
- YTD
- +32.16%
- 1 year
- -40.82%
- Open
- 10.15
- Prev close
- 10.15
- Mkt cap
- 268.52M
- Vol
- 11.01M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.15
- High
- 10.15
- Forward P/E
- -1.26
- Beta
- 1.39
- Short ratio
- 3.66
- Inst. own
- 103.92%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 8.57
- 200-d avg
- 12.79
- 1y target
- 25.00
News
1 year ago prnewswire.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and KLG on Behalf of Shareholders
NEW YORK , Aug. 20, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or…
1 year ago globenewswire.com
ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS
NEW YORK and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the…
1 year ago businesswire.com
ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
1 year ago globenewswire.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or…
1 year ago prnewswire.com
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc.
NEW YORK , July 21, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by iTeos Therapeutics, Inc. (NASDAQ: ITOS) and its board of directors concerning the…
1 year ago globenewswire.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of iTeos Therapeutics, Inc. (NASDAQ: ITOS)
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and…
1 year ago businesswire.com
ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of iTeos Therapeutics, Inc. (NASDAQ: ITOS) to Concentra Biosciences, LLC is fair to iTeos…
1 year ago globenewswire.com
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (“iTeos”) (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement…
1 year ago zacks.com
iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know
iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
1 year ago globenewswire.com
iTeos Therapeutics Announces Its Intention to Wind Down Operations
- Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984,…
1 year ago globenewswire.com
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival
1 year ago zacks.com
Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?
The consensus price target hints at a 211.1% upside potential for iTeos Therapeutics (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in…
1 year ago globenewswire.com
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash…
1 year ago globenewswire.com
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and…
1 year ago globenewswire.com
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Completed…
1 year ago seekingalpha.com
iTeos Therapeutics: Decimated By Collateral Events, Good Chances Of Success Nevertheless
iTeos' lead molecule, Belrestotug, shows promising efficacy in trials despite setbacks in the anti-TIGIT space, with significant partnerships and a strong cash position. The stock has suffered due to…
1 year ago zacks.com
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy
iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
1 year ago seekingalpha.com
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
iTeos Therapeutics, Inc.'s lead candidate, belrestotug, shows promising response rates in lung cancer but faces challenges with increased toxicity and skepticism due to past failures in similar…
1 year ago globenewswire.com
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts -…
1 year ago globenewswire.com
iTeos to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development…
-
2 years ago benzinga.com
Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
-
2 years ago benzinga.com
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
-
2 years ago benzinga.com
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
-
2 years ago benzinga.com
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
-
3 years ago benzinga.com
Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.
-
3 years ago benzinga.com
Wyndham Hotels & Resorts, Olink Holding And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 50 points on Tuesday. Here are some big stocks recording gains in today’s session.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday saw 132 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 647 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 369 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 406 companies made new 52-week lows.
-
3 years ago benzinga.com
Why Grab Holdings Are Trading Higher By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers AgileThought, Inc. (NASDAQ: AGIL) jumped 85.5% to $0.3941. AgileThought recently posted a loss for the second quarter.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 210 companies reached new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's session, 201 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 155 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 188 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 469 companies hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 175 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 337 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 540 companies set new 52-week lows.
-
4 years ago benzinga.com
99 Biggest Movers From Yesterday
Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company.
-
4 years ago benzinga.com
52 Stocks Moving In Wednesday's Mid-Day Session
Gainers Trecora Resources (NYSE: TREC) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of Balmoral Funds at $9.81 per share in cash or an enterprise value of $247…
-
4 years ago benzinga.com
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
-
5 years ago benzinga.com
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter.
-
5 years ago benzinga.com
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
On Wednesday morning, 198 companies hit new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
On Tuesday, 596 companies set new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
Monday morning saw 558 companies set new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
During the morning session on Friday, 389 stocks hit new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
Tuesday's morning session saw 269 companies set new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Friday
Friday's session saw 466 companies set new 52-week highs.